Toward the harmonization of immune monitoring in clinical trials: quo vadis?

doi:10.1007/s00262-007-0379-z

Comment

. 2008 Mar;57(3):285-8.

doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25.

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

C M Britten¹, S Janetzki, S H van der Burg, C Gouttefangeas, A Hoos

Affiliations

PMID: 17721782
PMCID: PMC2150641
DOI: 10.1007/s00262-007-0379-z

Comment

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

C M Britten et al. Cancer Immunol Immunother. 2008 Mar.

. 2008 Mar;57(3):285-8.

doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25.

Authors

C M Britten¹, S Janetzki, S H van der Burg, C Gouttefangeas, A Hoos

Affiliation

¹ Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. cebritten@web.de

PMID: 17721782
PMCID: PMC2150641
DOI: 10.1007/s00262-007-0379-z

No abstract available

PubMed Disclaimer

Comment on

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Janetzki S, et al. Cancer Immunol Immunother. 2008 Mar;57(3):303-15. doi: 10.1007/s00262-007-0380-6. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721781 Free PMC article.
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.
Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. Britten CM, et al. Cancer Immunol Immunother. 2008 Mar;57(3):289-302. doi: 10.1007/s00262-007-0378-0. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721783 Free PMC article.

Cited by

Dendritic cell vaccination and immune monitoring.
Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Aarntzen EH, et al. Cancer Immunol Immunother. 2008 Oct;57(10):1559-68. doi: 10.1007/s00262-008-0553-y. Epub 2008 Jul 10. Cancer Immunol Immunother. 2008. PMID: 18618110 Free PMC article. Review.
Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines.
Mander A, Chowdhury F, Low L, Ottensmeier CH. Mander A, et al. Cancer Immunol Immunother. 2009 May;58(5):789-800. doi: 10.1007/s00262-008-0633-z. Epub 2008 Dec 10. Cancer Immunol Immunother. 2009. PMID: 19066888 Free PMC article.
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.
Li XD, Ji M, Zheng X, Ning ZH, Wu J, Lu B, Wu CP, Jiang JT. Li XD, et al. J Transl Med. 2014 Aug 12;12:215. doi: 10.1186/s12967-014-0215-0. J Transl Med. 2014. PMID: 25113800 Free PMC article. Review.
Ancillary study management systems: a review of needs.
Nelson EK, Piehler B, Rauch A, Ramsay S, Holman D, Asare S, Asare A, Igra M. Nelson EK, et al. BMC Med Inform Decis Mak. 2013 Jan 7;13:5. doi: 10.1186/1472-6947-13-5. BMC Med Inform Decis Mak. 2013. PMID: 23294514 Free PMC article.
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Waerlop G, Leroux-Roels G, Lambe T, Bellamy D, Medaglini D, Pettini E, Cox RJ, Trieu MC, Davies R, Bredholt G, Montomoli E, Gianchecchi E, Clement F. Waerlop G, et al. Front Immunol. 2022 Sep 8;13:984642. doi: 10.3389/fimmu.2022.984642. eCollection 2022. Front Immunol. 2022. PMID: 36159843 Free PMC article.

See all "Cited by" articles

References

1. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother. 2004;53:249. doi: 10.1007/s00262-003-0473-9. - DOI - PMC - PubMed
1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909. doi: 10.1038/nm1100. - DOI - PMC - PubMed
1. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. Cancer vaccine clinical trial working groupA clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1. doi: 10.1097/01.cji.0000211341.88835.ae. - DOI - PubMed
1. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’Souza MP. Elispot collaborative study group results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68. doi: 10.1089/aid.2005.21.68. - DOI - PubMed
1. Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005;302:51. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother. 2004;53:249. doi: 10.1007/s00262-003-0473-9. - DOI - PMC - PubMed

[2] Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother. 2004;53:249. doi: 10.1007/s00262-003-0473-9. - DOI - PMC - PubMed

[3] Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909. doi: 10.1038/nm1100. - DOI - PMC - PubMed

[4] Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909. doi: 10.1038/nm1100. - DOI - PMC - PubMed

[5] Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. Cancer vaccine clinical trial working groupA clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1. doi: 10.1097/01.cji.0000211341.88835.ae. - DOI - PubMed

[6] Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. Cancer vaccine clinical trial working groupA clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1. doi: 10.1097/01.cji.0000211341.88835.ae. - DOI - PubMed

[7] Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’Souza MP. Elispot collaborative study group results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68. doi: 10.1089/aid.2005.21.68. - DOI - PubMed

[8] Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’Souza MP. Elispot collaborative study group results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68. doi: 10.1089/aid.2005.21.68. - DOI - PubMed

[9] Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005;302:51. - PubMed

[10] Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol. 2005;302:51. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

Affiliation

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

Authors

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources